4-氧代-4,5,6,7-四氢-2H-吡咯并[3,4-c]吡啶-1-甲醛 | 358732-55-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 4-氧代-4,5,6,7-四氢-2H-吡咯并[3,4-c]吡啶-1-甲醛
• 中文别名: 6-氨基哒嗪-3-甲腈
• 英文名称: 4-oxo-4,5,6,7-tetrahydro-2H-pyrrolo[3,4-c]pyridine-1-carbaldehyde
• 英文别名: 4-oxo-2,5,6,7-tetrahydropyrrolo[3,4-c]pyridine-1-carbaldehyde
• CAS: 358732-55-5
• 化学式: C₈H₈N₂O₂
• 分子量: 164.164
• InChiKey: APWBRBDLKHNDAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  62
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,3-二氢-4-(2-羟乙基)-2H-吲哚-2-酮 、 4-氧代-4,5,6,7-四氢-2H-吡咯并[3,4-c]吡啶-1-甲醛 在 哌啶 作用下， 以 乙醇 为溶剂， 生成 1-[4-(2-hydroxy-ethyl)-2-oxo-1,2-dihydro-indol-3-ylidenemethyl]-2,5,6,7-tetrahydro-pyrrolo[3,4-c]pyridin-4-one
  参考文献：
  名称：

  Novel pyrrolyllactone and pyrrolyllactam indolinones as potent cyclin-Dependent kinase 2 inhibitors

  摘要：

  Cyclin-dependent kinases (CDKs) are essential in the control of cell cycle progression. Inhibition of CDKs represents a new approach for pharmacological intervention in the treatment of a variety of proliferative diseases, especially cancer. Based on the crystal structure of CDK2 in complex with an imidazole indolinone compound 1 (SU9516), lead optimization through modeling, synthesis, and SAR studies has led to the discovery of a novel series of pyrrolyllactone and pyrrolyllactam indolinones as potent CDK2 inhibitors. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00312-3
• 作为产物：
  描述：

  1-Boc-2-哌啶酮 在 六甲基磷酰三胺 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 间氯过氧苯甲酸 、 三氟乙酸 、 lithium diisopropyl amide 、 三氯氧磷 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 生成 4-氧代-4,5,6,7-四氢-2H-吡咯并[3,4-c]吡啶-1-甲醛
  参考文献：
  名称：

  Novel pyrrolyllactone and pyrrolyllactam indolinones as potent cyclin-Dependent kinase 2 inhibitors

  摘要：

  Cyclin-dependent kinases (CDKs) are essential in the control of cell cycle progression. Inhibition of CDKs represents a new approach for pharmacological intervention in the treatment of a variety of proliferative diseases, especially cancer. Based on the crystal structure of CDK2 in complex with an imidazole indolinone compound 1 (SU9516), lead optimization through modeling, synthesis, and SAR studies has led to the discovery of a novel series of pyrrolyllactone and pyrrolyllactam indolinones as potent CDK2 inhibitors. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00312-3

文献信息

• 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
  申请人：——

  公开号：US20020187978A1

  公开（公告）日：2002-12-12

  The present invention relates to certain 4-heteroaryl-3-heteroarylidenyl-2-indolinones compounds and their physiologically acceptable salts which modulate the activity of protein kinases (“PKs”), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.

  本发明涉及某些4-杂环芳基-3-杂环芳基亚亚基-2-吲哚酮化合物及其生理上可接受的盐，这些化合物调节蛋白激酶（“PKs”）的活性，特别是CDK2。因此，本发明的化合物在治疗与异常PK活性相关的疾病方面是有用的。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
  申请人：——

  公开号：US20020042427A1

  公开（公告）日：2002-04-11

  The invention relates to certain indolinone compounds, their method of synthesis, and a combinatorial library consisting of the indolinone compounds of the invention. The invention also relates to methods of modulating the function of protein kinases using indolinone compounds of the invention and methods of treating diseases by modulating the function of protein kinases and related signal transduction pathways.

  该发明涉及某些吲哚酮化合物，它们的合成方法，以及由该发明的吲哚酮化合物组成的组合库。该发明还涉及使用该发明的吲哚酮化合物调节蛋白激酶功能的方法，以及通过调节蛋白激酶功能和相关信号传导途径治疗疾病的方法。
• 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
  申请人：Sugen, Inc.

  公开号：US20040097497A1

  公开（公告）日：2004-05-20

  The present invention relates to certain 4-heteroaryl-3-heteroarylidenyl-2-indolinones compounds and their physiologically acceptable salts which modulate the activity of protein kinases (“PKs”), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.

  本发明涉及某些4-杂环芳基-3-杂环芳基亚甲基-2-吲哚酮化合物及其生理上可接受的盐，其调节蛋白激酶（“PKs”）的活性，特别是CDK2。因此，本发明的化合物在治疗与异常PK活性相关的疾病方面是有用的。还描述了含有这些化合物的制药组合物和制备这些化合物的方法。
• Bi-functional complexes and methods for making and using such complexes
  申请人：Gouliaev Alex Haahr

  公开号：US11225655B2

  公开（公告）日：2022-01-18

  The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.

  本发明涉及一种合成双功能复合物的方法，该复合物包括分子部分和识别分子部分的识别寡核苷酸部分。根据本发明的合成方法的一部分优选在一种或多种有机溶剂中进行，此时包含可选保护标签或寡核苷酸标识符的新生双功能复合物与固体支持物相连接，合成方法的另一部分优选在适合于将寡核苷酸标签酶加到溶液中的新生双功能复合物的条件下进行。
• 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS
  申请人：Sugen, Inc.

  公开号：EP1259514A2

  公开（公告）日：2002-11-27